Facebook Pixel How AI Is Accelerating Drug Repurposing & Therapeutic Innovation in India | Bio Spectrum - business - Lee esta historia en Magzter.com

Intentar ORO - Gratis

How AI Is Accelerating Drug Repurposing & Therapeutic Innovation in India

Bio Spectrum

|

October 2025

With India facing increasing disease burdens and deficiencies in healthcare infrastructure, AI is becoming a driving force for quicker, more intelligent therapeutic advancements. Indian startups and institutions are making significant contributions through drug repurposing, enhancing diagnostics, genomics, and clinical research.

How AI Is Accelerating Drug Repurposing & Therapeutic Innovation in India

India's healthcare system is at a pivotal moment. The numbers tell a stark story - noncommunicable diseases now cause 66 per cent of all deaths while a staggering 2.4 million hospital bed shortfall intensifies the pressure on limited infrastructure. Add to that a highly cost-sensitive market where over 50 per cent of healthcare expenses are paid out-of-pocket, and the urgency for faster, more efficient treatment pathways becomes clear.

One promising solution gaining momentum is drug repurposing - the game changing strategy of finding new therapeutic uses for existing drugs. This is accelerated by the growing adoption of artificial intelligence (AI) tools that can cut early-stage development costs by up to 50 per cent.

AI plays a crucial role in unlocking the full potential of drug repurposing by analysing vast and complex datasets such as clinical records, biomedical literature, molecular pathways, and real-world evidence to uncover hidden drug-disease relationships. Unlike traditional methods, AI enables faster hypothesis generation, predictive modeling, and risk profiling at scale. In India, where time and cost constraints are particularly acute, this ability to accelerate discovery and reduce trial-and-error makes AI not just a helpful tool, but a transformative enabler across drug development and other therapeutic areas like oncology, rare diseases, and infectious conditions.

AI in Drug Repurposing: Use Cases from India

AI-powered drug repurposing is rewriting the rulebook, cutting development time and costs by 50-60 per cent compared to building drugs from scratch. Across India, pioneering platforms are harnessing machine learning, natural language processing, and molecular modeling to breathe new life into existing compounds

Game changing AI workflows in action

MÁS HISTORIAS DE Bio Spectrum

Bio Spectrum

Bio Spectrum

MAHE teams up with OpenAI to integrate AI to enhance outcomes

Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Jubilant Bhartia Foundation & McGill University to launch CoE in AI education

The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Heeding Auditory Warning Signs

By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).

time to read

2 mins

April 2026

Bio Spectrum

Bio Spectrum

Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer

Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer

Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow

Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

UK deploys new bone scanners to help prevent fractures

Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Cytiva expands Fast Trak process development and validation services facility in India

Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

ΑΙ TAKES INDIAN PHARMA REINS

The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.

time to read

10 mins

April 2026

Bio Spectrum

NIH halts arm of clinical trial evaluating potential stroke treatment

The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).

time to read

1 min

April 2026

Listen

Translate

Share

-
+

Change font size